Atara Biotherapeutics vs ImmunityBio
Atara Biotherapeutics reported revenue of $121 million in fiscal 2025, about the same as ImmunityBio's $113 million in fiscal 2025. Atara Biotherapeutics' revenue fell 6.3% in its latest year, and ImmunityBio's grew 668.3%. Atara Biotherapeutics had an operating margin of 29.7%, against -226.0% at ImmunityBio. Free cash flow was −$51 million at Atara Biotherapeutics and −$309 million at ImmunityBio.
Side by side
| Atara Biotherapeutics | ImmunityBio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $121M | $113M |
| Revenue growth | −6.3% | 668.3% |
| Revenue growth a year, last 5 years | — | 185.2% |
| Gross margin | — | 99.3% |
| Operating margin | 29.7% | −226.0% |
| Net margin | 27.1% | −310.2% |
| Free cash flow | −$51M | −$309M |
| Free cash flow margin | −42.2% | −272.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 69.8% | 31.3% |
| Last close | $6.34 | $6.57 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $5.7 million, sold $3.8 million | sold $8.4 million |
| Piotroski F-score | — | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Atara BiotherapeuticsImmunityBio
Operating margin
Percent of revenue
Atara BiotherapeuticsImmunityBio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Atara BiotherapeuticsImmunityBio
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Atara Biotherapeutics and ImmunityBio pages.